HIT trial: CAD-1005 patients had 50% clot rate vs >75% on placebo

NodeGuardian

2026-03-12 12:43:00

Abstract generation in progress

Cadrenal Therapeutics reported encouraging Phase 2 results for CAD-1005 in heparin-induced thrombocytopenia (HIT), showing a greater than 25% absolute reduction in thrombotic events compared to placebo. While the drug did not improve platelet count recovery, patients receiving CAD-1005 experienced fewer thrombotic events (50%) compared to the placebo group (>75%). An End-of-Phase 2 FDA meeting is scheduled for March 2026 to discuss the path forward for a Phase 3 study.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.